Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
McKesson Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $87.2B | |
|---|---|---|
| Revenue (ttm) | 411B | |
| Net income (ttm) | 4.6B | |
| EPS (ttm) | $37.5 | |
| Shares out | 116.6M | |
| P/E (trailing) | 25.6x | |
| P/E (forward) | 14.4x | |
| Dividend | $3.76 (0.39%) | |
| Volume | 623,059 | |
| Beta | 0.30 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | Trend |
| Revenue | $263.97B | $276.71B | $308.95B | $359.05B | +10.8% |
| Gross profit | $13.13B | $12.36B | $12.83B | $13.32B | +0.5% |
| Operating income | $2.11B | $4.88B | $4.04B | $4.62B | +30.0% |
| Net income | $1.11B | $3.56B | $3.00B | $3.30B | +43.5% |
| EPS (diluted) | $7.23 | $25.03 | $22.39 | $25.72 | +52.7% |
| EBITDA | $2.87B | $5.49B | $4.68B | $5.26B | +22.4% |
| R&D | — | — | — | — | — |
| SG&A | $10.54B | $7.78B | $8.66B | $8.51B | -6.9% |
Recent company headlines from major financial publishers.
Expansion into higher-margin specialty and oncology services successfully transforms the revenue mix. Operating margins expand, and steady cash flows fuel aggressive buybacks, pushing value to the $1,308 high.
McKesson maintains its dominant oligopoly position. Predictable cash flows support steady share repurchases and dividends. Forward earnings trajectory bypasses WACC anomalies to deliver a $1,016 intrinsic value.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 3.5% | $1,168 | $1,558 | $1,561 | $1,561 | $1,561 |
| 4.1% | $892 | $1,102 | $1,442 | $1,561 | $1,561 |
| 5.1% | $645 | $749 | $892 | $1,102 | $1,442 |
| 6.1% | $506 | $567 | $645 | $749 | $892 |
| 7.1% | $491 | $491 | $506 | $567 | $645 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
